Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
March 19, 2010
Program to improve bar-code print quality
Ronald Schneider, Russell Carlson, Chris Tucker, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
June 6, 2009
Quality-monitoring program for bar-code-assisted medication administration
Elizabeth Mims, Chris Tucker, Russ Carlson, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2007
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
Holly J Meany, Elizabeth Fox, Cynthia McCully, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
February 15, 2022
Probing Covalent Interactions at a Silicone Adhesive/Nylon Interface
Ting Lin, Yuchen Wu, Elizabeth Santos, et al.
Veterinary Therapeutics : Research in Applied Veterinary Medicine
|
May 12, 2004
Field evaluation of moxidectin/praziquantel oral gel in horses
Steven T Grubbs, Debbie Amodie, Dino Rulli, et al.
Cancer Chemotherapy and Pharmacology
|
July 14, 2017
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent
Christos Fountzilas, Ravi Chhatrala, Nikhil Khushalani, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
December 25, 2013
HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation
Janitza L Montalvo-Ortiz, Jack Keegan, Christopher Gallardo, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
March 28, 2013
Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
Ronald A Lubet, Eva Szabo, Kenneth K Iwata, et al.
Cancer Chemotherapy and Pharmacology
|
November 22, 2007
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
Laura K Zerbe, Lori D Dwyer-Nield, Jason M Fritz, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
April 6, 2011
Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms
Steven Lipkin, John Lee, David Imagawa, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
March 19, 2010
Program to improve bar-code print quality
Ronald Schneider, Russell Carlson, Chris Tucker, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
June 6, 2009
Quality-monitoring program for bar-code-assisted medication administration
Elizabeth Mims, Chris Tucker, Russ Carlson, et al.
Cancer Chemotherapy and Pharmacology
|
October 13, 2007
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates
Holly J Meany, Elizabeth Fox, Cynthia McCully, et al.
Langmuir : the ACS Journal of Surfaces and Colloids
|
February 15, 2022
Probing Covalent Interactions at a Silicone Adhesive/Nylon Interface
Ting Lin, Yuchen Wu, Elizabeth Santos, et al.
Veterinary Therapeutics : Research in Applied Veterinary Medicine
|
May 12, 2004
Field evaluation of moxidectin/praziquantel oral gel in horses
Steven T Grubbs, Debbie Amodie, Dino Rulli, et al.
Cancer Chemotherapy and Pharmacology
|
July 14, 2017
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent
Christos Fountzilas, Ravi Chhatrala, Nikhil Khushalani, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
December 25, 2013
HDAC inhibitors restore the capacity of aged mice to respond to haloperidol through modulation of histone acetylation
Janitza L Montalvo-Ortiz, Jack Keegan, Christopher Gallardo, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
March 28, 2013
Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
Ronald A Lubet, Eva Szabo, Kenneth K Iwata, et al.
Cancer Chemotherapy and Pharmacology
|
November 22, 2007
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
Laura K Zerbe, Lori D Dwyer-Nield, Jason M Fritz, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
April 6, 2011
Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms
Steven Lipkin, John Lee, David Imagawa, et al.
Page
of 2